2.2.6 MORF-057 MORF-057 is an oral small-molecule inhibitor of 47 integrin that blocks lymphocyte recruitment to the gut and was evaluated in the EMERALD-1 study (NCT05291689), an open-label Phase 2a single-arm multicenter trial where 35 participants with moderately to severely active UC received 100 mg twice daily for 52 weeks following a 6-week screening period
GHK-Cu GHK-Cu ( , COPPER TRIPEPTIDE-1) - , 3 , ,
A 12-week facial cream study in 71 women documented increased skin density and thickness, reduced laxity, improved clarity, and reduced fine lines with wrinkle depth decreased significantly
Multiple endocrine neoplasia type 2 with Hirschsprung disease is also an uncommon variant in which affected family members develop Hirschsprung disease (88,107) The penetrance varies considerably
410225) and N-acetylcysteine (Catalog No
Search Cart 0 My Vazyme 0 Email Email [email protected] Contact Us TOP Documents Product Center